These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31110830)

  • 1. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.
    Mallipudi RM; Alquran L; Shenoy VA; Leslie LA; Conti JA
    Case Rep Oncol Med; 2019; 2019():4121234. PubMed ID: 31110830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.
    Asrani R; Cengiz TB; Petersen BE; Anagnostou T; Brody JD
    Front Oncol; 2023; 13():1254256. PubMed ID: 38313213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
    Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
    Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
    Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
    Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I manage patients with grey zone lymphoma.
    Kritharis A; Pilichowska M; Evens AM
    Br J Haematol; 2016 Aug; 174(3):345-50. PubMed ID: 27301470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
    Svoboda J; Bair SM; Landsburg DJ; Dwivedy Nasta S; Nagle SJ; Barta SK; Khan N; Filicko-O'Hara J; Gaballa S; Strelec L; Chong E; Mitnick S; Waite TS; King C; Ballard H; Youngman M; Gerson J; Plastaras JP; Maity A; Bogusz AM; Hung SS; Nakamura H; Nejati R; Steidl C; Lim M; Ruella M; Schuster SJ
    Haematologica; 2021 Jun; 106(6):1705-1713. PubMed ID: 32414850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.
    Hojo N; Nagasaki M; Mihara Y
    World J Clin Cases; 2022 Jun; 10(17):5708-5716. PubMed ID: 35979119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
    Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
    Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
    Wang L; Wang W; Li X; Guo Y; Zhu X
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the Mystery of Gray Zone Lymphoma in Human Immunodeficiency Virus-Seropositive Patients: Two Cases.
    Ahluwalia A; Bondili L; Salamera J; Cholankeril M
    J Hematol; 2020 Dec; 9(4):132-136. PubMed ID: 33224393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
    Pilichowska M; Pittaluga S; Ferry JA; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Kritharis A; Hernandez-Ilizaliturri FJ; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA; Jagadeesh D; Woda B; Gupta GK; Gascoyne RD; Jaffe ES; Evens AM
    Blood Adv; 2017 Dec; 1(26):2600-2609. PubMed ID: 29296913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
    Makita S; Maruyama D; Tobinai K
    Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of 10 cases of brentuximab vedotin combined with chemotherapy in the treatment of children with refractory and or relapsed classic Hodgkin lymphoma].
    Li N; Li Y; Zhou CJ; Huang S; Jin L; Yang J; Shao MM; Sun H; Wang XL; Duan YL
    Zhonghua Er Ke Za Zhi; 2024 Jul; 62(8):775-779. PubMed ID: 39039881
    [No Abstract]   [Full Text] [Related]  

  • 19. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
    Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
    Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
    Berger GK; McBride A; Lawson S; Royball K; Yun S; Gee K; Bin Riaz I; Saleh AA; Puvvada S; Anwer F
    Crit Rev Oncol Hematol; 2017 Jan; 109():42-50. PubMed ID: 28010897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.